AstraZeneca signs strategic partnership with Beijing; invests $2.5bn

The pharmaceutical firm expects its workforce in Beijing to grow to 1,700 employees and is launching a JV with BioKangtai to help make vaccines; there is also investment into AI.

UK and Swedish pharmaceutical giant AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic research & development (R&D) centre, according to a March 21 announcement.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media